Tissue Programmed Hydrogels Functionalized with GDNF Improve Human Neural Grafts in Parkinson's Disease

被引:21
|
作者
Hunt, Cameron P. J. [1 ]
Penna, Vanessa [1 ]
Gantner, Carlos W. [1 ]
Moriarty, Niamh [1 ]
Wang, Yi [2 ,3 ]
Franks, Stephanie [2 ,3 ]
Ermine, Charlotte M. [1 ]
de Luzy, Isabelle R. [1 ]
Pavan, Chiara [1 ]
Long, Benjamin M. [4 ]
Williams, Richard J. [5 ]
Thompson, Lachlan H. [1 ]
Nisbet, David R. [2 ,3 ,6 ,7 ]
Parish, Clare L. [1 ]
机构
[1] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia
[2] Australian Natl Univ, Res Sch Chem, Lab Adv Biomat, Canberra, ACT 2601, Australia
[3] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia
[4] Federat Univ, Sch Hlth & Life Sci, Mt Helen, Vic 3353, Australia
[5] Deakin Univ, Sch Med, Ctr Mol & Med Res, Waurn Ponds, Vic 3216, Australia
[6] Univ Melbourne, Graeme Clark Inst, Fac Engn & Informat Technol, Melbourne, Australia
[7] Univ Melbourne, Fac Med Dent & Hlth Serv, Melbourne, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会; 欧盟地平线“2020”;
关键词
biomaterials; dopamine; glial cell line-derived neurotrophic factor; hydrogels; laminin; Parkinson's disease; self-assembling peptides; stem cells; transplantation; MIDBRAIN DOPAMINE NEURONS; STEM-CELL; NEUROTROPHIC FACTOR; PROGENITOR CELLS; RAT MODEL; TRANSPLANTS; SCAFFOLDS; SURVIVAL; GROWTH; INTEGRATION;
D O I
10.1002/adfm.202105301
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The survival and synaptic integration of transplanted dopaminergic (DA) progenitors are essential for ameliorating motor symptoms in Parkinson's disease (PD). Human pluripotent stem cell (hPSC)-derived DA progenitors are, however, exposed to numerous stressors prior to, and during, implantation that result in poor survival. Additionally, hPSC-derived grafts show inferior plasticity compared to fetal tissue grafts. These observations suggest that a more conducive host environment may improve graft outcomes. Here, tissue-specific support to DA progenitor grafts is provided with a fully characterized self-assembling peptide hydrogel. This biomimetic hydrogel matrix is programmed to support DA progenitors by i) including a laminin epitope within the matrix; and ii) shear encapsulating glial cell line-derived neurotrophic factor (GDNF) to ensure its sustained delivery. The biocompatible hydrogel biased a 51% increase in A9 neuron specification-a subpopulation of DA neurons critical for motor function. The sustained delivery of GDNF induced a 2.7-fold increase in DA neurons and enhanced graft plasticity, resulting in significant improvements in motor deficits at 6 months. These findings highlight the therapeutic benefit of stepwise customization of tissue-specific hydrogels to improve the physical and trophic support of human PSC-derived neural transplants, resulting in improved standardization, predictability and functional efficacy of grafts for PD.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Intraventricular administration of GDNF in the treatment of Parkinson's disease
    Nutt, JG
    Bronstein, JM
    Carter, JH
    Comella, CL
    Cravets, M
    Davis, TL
    Jankovic, J
    Klein, M
    Koller, WC
    Lang, AE
    Lee, DR
    O'Brien, CF
    Pahwa, R
    Schultz, B
    Siemers, ER
    Stacy, M
    Thomas-Lukes, K
    Trugman, JM
    Tuite, PJ
    Weiner, WJ
    Wooten, GF
    NEUROLOGY, 2001, 56 (08) : A375 - A375
  • [22] GDNF trial: promising results for Parkinson's disease
    Butcher, J
    LANCET NEUROLOGY, 2003, 2 (05): : 265 - 265
  • [23] Human Tissue Used for Research on Parkinson's Disease
    不详
    ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2013, 41 (05): : 329 - 329
  • [24] Programmed Cell Death in Parkinson's Disease
    Venderova, Katerina
    Park, David S.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (08):
  • [25] Programmed cell death and Parkinson's disease
    Burke, RE
    MOVEMENT DISORDERS, 1998, 13 : 17 - 23
  • [26] Sustained delivery of GDNF: towards a treatment for Parkinson's disease
    Zurn, AD
    Widmer, HR
    Aebischer, P
    BRAIN RESEARCH REVIEWS, 2001, 36 (2-3) : 222 - 229
  • [27] GDNF-based cell therapy in Parkinson's Disease
    Lopez-Barneo, J.
    HUMAN GENE THERAPY, 2013, 24 (12) : A23 - A23
  • [28] Gene transfer techniques for the delivery of GDNF in Parkinson's disease
    Ridet, JL
    Déglon, N
    Aebischer, P
    NEURAL TRANSPLANTATION IN NEURODEGENERATIVE DISEASE: CURRENT STATUS AND NEW DIRECTIONS, 2000, 231 : 202 - 215
  • [29] Human neural stem cells on trial for Parkinson's disease
    Fricker, J
    MOLECULAR MEDICINE TODAY, 1999, 5 (04): : 144 - 144
  • [30] GDNF's Role in Mitigating Intestinal Reactive Gliosis and Inflammation to Improve Constipation and Depressive Behavior in Rats with Parkinson's disease
    Qin, Xiaoling
    Guo, Yurong
    Ke, Xue
    Qiu, Yuxiang
    An, Panpan
    Du, Yinzhen
    Xue, Li
    Liu, Tingting
    Tang, Chuanxi
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2024, 74 (03)